PWMG
INM icon

Private Wealth Management Group’s InMed Pharmaceuticals INM Stock Holding History

Private Wealth Management Group’s Portfolio INM Stock Details INM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.75K Hold
5,000
– – ﹤0.01% 658
2026
Q1 		$3.23K Buy
+5,000
New +$4.71K ﹤0.01% 920

Other funds holding INM

ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
UFM
Ursa Fund Management Danville, California $1.28B AUM 89.08% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Private Wealth Management Group's INM Position: Q2 2026 in Review

Private Wealth Management Group held its InMed Pharmaceuticals (INM) position steady in Q2 2026 at 5,000 shares worth $7.75K. The position accounts for ﹤0.01% of the portfolio, ranked #658.

Private Wealth Management Group first reported a position in INM in Q1 2026 and has held it in 2 quarters since. 20 funds tracked by Wall St. Rank hold INM as of Q2 2026.

  • Private Wealth Management Group held 5,000 shares of InMed Pharmaceuticals worth $7.75K as of Q2 2026.
  • Private Wealth Management Group left its InMed Pharmaceuticals share count unchanged in Q2 2026.
  • InMed Pharmaceuticals made up ﹤0.01% of Private Wealth Management Group's portfolio in Q2 2026, its #658 holding.
  • Private Wealth Management Group first reported a position in InMed Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 20 funds tracked by Wall St. Rank held InMed Pharmaceuticals as of Q2 2026.

Based on Private Wealth Management Group's 13F filing for Q2 2026, filed 27 Jul 2026.